Getinge Group Interim Report January - June 2013 Business Wire GETINGE, Sweden -- July 11, 2013 Regulatory News: Getinge AB (STO:GETIB): Reporting period January – June *Order intake rose by 3.8% to SEK 12,483 M (12,025), and grew organically by 3.7% *Net sales increased by 7.6% to SEK 11,680 M (10,858), and grew organically by 7.0% *Profit before tax was SEK 878 M (1,285) *Net profit totalled SEK 641 M (951) *Earnings per share amounted to SEK 2.67 (3.98) *EBITA before restructuring declined by 4.1% to SEK 1,797 M (1,873). Adjusted for exchange-rate effects and the tax on medical-technical products introduced in the US, EBITA rose by 9.7% Reporting period April – June *Order intake rose by 4.6% to SEK 6,515 M (6,230), and grew organically by 5.4% *Net sales increased by 7.2% to SEK 6,015 M (5,612), and grew organically by 7.3% *Profit before tax was SEK 626 M (716). *EBITA before restructuring declined by 1.5% to SEK 1,004 M (1,019). Adjusted for exchange-rate effects and the tax on medical-technical products introduced in the US, EBITA rose by 10.9% Second quarter 2013 Order intake improved during the period and the potential for the Group to achieve an organic growth exceeding that of the preceding year has increased. Although the product and market mix were challenging during the quarter, when adjusted for the negative exchange-rate fluctuations and the recently introduced tax on medical-technical products in the US, operating profit improved to a satisfactory degree. Teleconference with CEO Johan Malmquist and CFO Ulf Grunander 11 July 2013 at 10:00 a.m. Swedish time Sweden: +46 (0) 8 5065 3937 UK: +44 (0) 20 3427 1910 Code: 5923551 GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care. The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was brought to you by Cision http://news.cision.com Contact: GETINGE Kornelia Rasmussen Group Communications Phone: +46 (0)10 335 5810 E-mail: firstname.lastname@example.org
Getinge Group Interim Report January - June 2013
Press spacebar to pause and continue. Press esc to stop.